Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
Real-world study evaluating post-resistance treatment strategies after CDK4/6 inhibitors, PIK3CA inhibitors, or trastuzumab deruxtecan in ad…
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease [Phase 3]
Phase 3 trial comparing Niraparib to placebo in HER2-negative breast cancer with BRCA mutation or triple-negative disease, with results repo…
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer [Phase 3]
A Phase III, multicenter randomized open-label trial is evaluating a PD-1 inhibitor with anti-vascular therapy and anthracycline/taxane-base…
-
CLINICAL_TRIALS withdrawal · 2025-07-16Clinical Trial Update: Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) [EARLY_Phase 1]
An early-phase 1 trial of cyclosporin A for triple-negative breast cancer with DNA damage repair deficiency has been withdrawn.
-
CLINICAL_TRIALS other · 2025-07-15Clinical Trial Update: A Compassionate Use Study of Leronlimab in Breast Cancer
This document reports that a compassionate-use study of leronlimab for metastatic triple-negative breast cancer is no longer available.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies [Phase 1, Phase 2]
SPEDOX-6, a single protein encapsulated doxorubicin, is being studied in Phase 1/2 trials for several advanced cancers and is currently recr…
-
CLINICAL_TRIALS trial_result · 2025-07-14Clinical Trial Update: A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors [Phase 1, Phase 2]
A clinical trial update announcing the termination of a Phase 1/2 study evaluating Fruquintinib in combination with Tislelizumab in adults w…
-
CLINICAL_TRIALS trial_result · 2025-07-11Clinical Trial Update: INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors [Phase 1]
A Phase 1 trial of INCB106385, alone or with immunotherapy, in advanced solid tumors has completed. The study includes multiple indications …
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer [Phase 3]
Phase 3 clinical trial update assessing an adjuvant treatment regimen for triple-negative breast cancer, involving initial EC-directed thera…
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer [Phase 2]
This document provides an update on a Phase 2 neoadjuvant trial of weekly carboplatin plus paclitaxel for triple-negative breast cancer; the…
-
CLINICAL_TRIALS research · 2025-07-09Clinical Trial Update: Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC) [NA]
This clinical trial investigates using imatinib to convert triple-negative breast cancer into estrogen receptor–positive breast cancer, and …
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Role of the Immune Environment in Response to Therapy in Breast Cancer
A clinical trial update from Penn Medicine describes a study on how the immune environment influences response to therapy in breast cancer, …
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors [Phase 1]
This Phase 1 trial assesses Autogene Cevumeran (RO7198457) as a single agent and in combination with atezolizumab across multiple locally ad…
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial update examining pembrolizumab with carboplatin and gemcitabine in metastatic triple-negative breast cancer.
-
CLINICAL_TRIALS withdrawal · 2025-07-03Clinical Trial Update: Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer [Phase 1]
A National Cancer Institute-sponsored Phase 1 trial evaluating adding ASTX660 (tolinapant) to eribulin for advanced triple-negative breast c…
-
CLINICAL_TRIALS trial_result · 2025-07-02Clinical Trial Update: Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy [Phase 2]
This Phase 2 clinical trial update evaluates pembrolizumab in patients with stage IV inflammatory breast cancer or triple-negative breast ca…
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: Trop-2 Targeted PET Probes in Advanced TNBC [NA]
A clinical trial update indicates Trop-2 targeted PET probes are being investigated for advanced triple-negative breast cancer and the study…
-
CLINICAL_TRIALS withdrawal · 2025-07-01Clinical Trial Update: A Study to Investigate LYL797 in Adults With Solid Tumors [Phase 1]
Lyell Immunopharma's Phase 1 study of LYL797 in adults with solid tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: A Biomarker Screening Protocol for Participants With Solid Tumors
A clinical trial update describes a biomarker screening protocol for participants with solid tumors, and the study has been terminated.
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer
This update covers a clinical trial evaluating the optimal combination of adjuvant radiotherapy and immunotherapy for breast cancer, includi…
-
CLINICAL_TRIALS research · 2025-06-25Clinical Trial Update: Personalized Vaccine for TNBC Immunotherapy [Phase 1]
A Phase 1 clinical trial evaluating a personalized vaccine for triple-negative breast cancer is listed as not yet recruiting.
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: HS-10502 Combination Treatment in Patients With Advanced Solid Tumors [Phase 1]
A Phase 1 clinical trial update for HS-10502 in patients with advanced solid tumors, including recurrent ovarian cancer and HER2-negative br…
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer [Phase 1, Phase 2]
A Phase 1/2 trial evaluating rintatolimod in combination with celecoxib, interferon alfa-2b, and pembrolizumab for metastatic or unresectabl…
-
CLINICAL_TRIALS research · 2025-06-23Clinical Trial Update: SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating SHR-A2102 in combination with Adebrelimab as neoadjuvant therapy for early-stage triple-negative breast cancer; t…
-
CLINICAL_TRIALS research · 2025-06-22Clinical Trial Update: Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer [Phase 2]
A Phase 2 feasibility trial evaluating adjuvant enzalutamide for early-stage androgen receptor-positive triple-negative breast cancer; the s…